NEW YORK (GenomeWeb News) – The Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence has been created with a $3.25 million gift from the Friedreich's Ataxia Research Alliance (FARA) in partnership with the Hamilton and Finneran families.

Friedreich's Ataxia (FA) is a progressive neurogenetic condition found in about one in every 50,000 people worldwide. No approved drugs currently exist for the condition, which is characterized by a progressive loss of coordinated movement and a loss of balance.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.